抗EGFR单抗类靶向药物在头颈部鳞癌综合治疗中的应用

头颈部肿瘤是世界上第6大常见的肿瘤。超过70%的头颈部肿瘤患者在首次确诊时即为局部晚期。尽管不断地努力改进治疗方法，但晚期病例的死亡率仍然居高不下。为了提高疗效，患者通常接受化疗、手术、放射治疗和分子靶向药物综合治疗。大量研究证实，表皮生长因子受体（epidermal growth factor receptor，EGFR）与肿瘤细胞的增殖和转移密切相关，EGFR在大多数头颈部肿瘤中高表达，对这些患者的预后有显著影响。抗EGFR单克隆抗体已经在一些国家被批准用于治疗局部晚期头颈鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）。本文综述了西妥昔单抗和尼妥珠单抗治疗HNSCC的研究进展。HNSCC的单克隆抗体靶向治疗，是选择西妥昔单抗还是尼妥珠单抗？本综述将围绕这一临床医生尤为关心的问题展开讨论。

Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma

Head and neck cancer is the sixth most common cancer worldwide. More than 70% of the patients with head and neck carcinoma present with locally advanced disease when initially confirmed. Despite intense efforts to improve different treatment modalities, mortality rates in advanced cases remain high. In order to improve the outcome, patients usually receive combined treatment with chemotherapy, surgery, radiotherapy and molecular targeted drugs. Lots of studies have confirmed that epidermal growth factor receptor (EGFR) is closely related to the proliferation and metastasis of tumor cells, and EGFR is overexpressed inmost head and neck cancer, which significantly affects the prognosis of those patients. Anti-EGFR monoclonal antibodies have been approved for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) in several countries. Here, we reviewed the scientific advances in HNSCC treated with cetuximab and nimotuzumab. Which one is better for treating the patients with HNSCC? Cetuximab or nimotuzumab? You will get some ideas from this review.